Allegations Include Off-label Marketing and Kickbacks to Doctors and Pharmacists
WASHINGTON—(ENEWSPF)—November 4, 2013. Global health care giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s…
